A5102735447- Parkinson's Disease Mechanisms and Treatments
- RNA regulation and disease
- Eating Disorders and Behaviors
- Stress Responses and Cortisol
- Genetic Neurodegenerative Diseases
- Alzheimer's disease research and treatments
- Nuclear Receptors and Signaling
- Ginkgo biloba and Cashew Applications
- Neurological disorders and treatments
- Cancer Mechanisms and Therapy
- Pulmonary Hypertension Research and Treatments
- Aortic Disease and Treatment Approaches
- Adipose Tissue and Metabolism
- Liver Disease Diagnosis and Treatment
- Quality and Safety in Healthcare
- Parasitic infections in humans and animals
- Coenzyme Q10 studies and effects
- Cardiac Valve Diseases and Treatments
- Advanced Neuroimaging Techniques and Applications
- Lysosomal Storage Disorders Research
- Cellular transport and secretion
- Child Nutrition and Feeding Issues
- Tryptophan and brain disorders
- MicroRNA in disease regulation
- Hepatitis C virus research
Universitat de Barcelona
2017-2024
Hospital Clínic de Barcelona
2015-2024
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2017-2024
Biomedical Research Networking Center on Neurodegenerative Diseases
2017-2024
Centro de Investigación Biomédica en Red
2022-2024
Instituto de Neurociencias
2024
Hospital Universitari de Vic
2022
Instituto de Salud Carlos III
2022
Universidad Complutense de Madrid
2022
Instituto de Investigación Sanitaria del Hospital Clínico San Carlos
2022
Isolated rapid eye movement sleep behavior disorder (IRBD) is a well-established clinical risk factor for Lewy body diseases (LBDs), such as Parkinson's disease (PD) and dementia with bodies (DLB).To elucidate whether serum microRNA (miRNA) deregulation in IRBD can antedate the diagnosis of LBD by performing longitudinal study different progression stages before after assessing predictive performance differentially expressed miRNAs machine learning-based modeling.Using genome-wide miRNA...
Abstract The LRRK2 G2019S pathogenic mutation causes LRRK2-associated Parkinson’s disease (L2PD) with incomplete penetrance. non-manifesting carriers (L2NMC) are at PD high risk but predicting pheno-conversion is challenging given the lack of progression biomarkers. To investigate novel biomarkers for premotor stages, we performed a longitudinal microRNA (miRNA) assessment serum samples from L2NMC followed-up over 8 years. Our cohort consisted stratified by dopamine transporter single-photon...
Abstract Objectives To conduct brainstem MRI shape analysis across neurodegenerative parkinsonisms and control subjects (CS), along with its association clinical cerebrospinal fluid (CSF) correlates. Methodology We collected demographic variables, performed planimetric analyses, determined CSF neurofilament-light chain (NfL) levels in 84 participants: 11 CS, 12 Parkinson’s disease (PD), 26 multiple system atrophy (MSA), 21 progressive supranuclear palsy (PSP), 14 corticobasal degeneration...
The clinicopathological phenotype of G2019S LRRK2-associated Parkinson's disease (L2PD) is similar to idiopathic (iPD), and LRRK2 nonmanifesting carriers (L2NMCs) are at increased risk for development PD. With various therapeutic strategies in the clinical preclinical pipeline, there an urgent need identify biomarkers that can aid early diagnosis patient enrichment ongoing future LRRK2-targeted trials.The objective this work was investigate differential protein phospho-protein changes...
Abstract Background and Objectives MicroRNA (miRNA) changes are observed in PD but remain poorly explored other α‐synucleinopathies such as MSA. Methods By genome‐wide analysis we profiled microRNA expression serum from 20 MSA cases compared to 40 controls. qPCR validated top differentially expressed microRNAs another sample of We also assessed the two consecutive sets 19 18 patients. Results In discovery set identified 25 associated with MSA, which related prion disease, fatty acid...
Abstract Background Some studies suggest that inflammatory signaling dysregulation may contribute to eating disorder (ED) pathophysiology. However, little is known about the influence of response on altered processes seen among patients with ED, such as emotional processing and reactivity. Objectives The objectives were: (a) investigate systemic in ED women; (b) analyze role markers Method Concentrations several intercellular intracellular mediators (cytokines, prostaglandin by‐products...
ABSTRACT Leucine-rich repeat kinase 2 (LRRK2) inhibition is a promising disease-modifying therapy for LRRK2-associated Parkinson’s disease (L2PD) and idiopathic PD (iPD). Yet, pharmaco-dynamic readouts progression biomarkers modification clinical trials are insufficient. Employing phospho-/proteomic analyses we assessed the impact that LRRK2 activating mutations had in peripheral blood mononuclear cells (PBMCs) from cohort Spain (n=174) encompassing G2019S L2PD patients (n=37),...
<h3>Background</h3> Malignant rhabdoid tumors (RT) are rare childhood tumors, initiating at embryonic development and manifesting in the kidney, soft tissues, or brain. Current treatment strategies include surgery, chemotherapy, radiation, but without biomarkers to personalize therapy selection duration, extremely poor patient prognosis is observed. While immune checkpoint inhibitors (ICI), such as anti-PD-L1 therapy, effective high mutational burden adult solid their value pediatric RT...
Abstract Leucine-rich repeat kinase 2 (LRRK2) inhibition is a promising disease-modifying therapy for LRRK2-associated Parkinson’s disease (L2PD) and idiopathic PD (iPD). However, pharmaco-dynamic readouts progression biomarkers clinical trials aiming modification are insufficient since no endogenous marker reflecting enhanced activity of the most common LRRK2 G2019S mutation has been reported yet in L2PD patients. Employing phospho-/proteomic analyses we assessed impact that activating...
The attempts to clarify the origin of eating disorders (ED) have not been completely successful and their etiopathogenesis remains unknown. Current research shows an activation immune response in neuropsychiatric diseases, including ED. We aimed investigate parameters patients with ED identify psychological factors influencing inflammatory response. relationship between inflammation markers impulsivity affective symptomatology was explored as well. Thirty-four adult female current diagnosis...
The purpose of this study was to investigate whether differential phosphorylation states blood markers can identify patients with LRRK2 Parkinson's disease (PD). We assessed phospho(P)-Ser-935-LRRK2 and P-Ser-473-AKT levels in peripheral cells from G2019S LRRK2-associated PD (L2PD, n = 31), non-manifesting carriers (L2NMC, 26), idiopathic (iPD, 25), controls (n 40, total 122). found no differences at P-Ser-935-LRRK2 between groups but detected a specific increase all carriers, either L2PD or...